Tandem Diabetes Care Stock News

Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a comp

Not every company has kept pace with the rising market, but some laggards could prove winners. Tandem Diabetes Care's innovative devices and long runway for growth should help turn things around.

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.

Matthew Taylor, senior analyst at Jefferies, joins 'The Exchange' to discuss the outlook for the med tech market, his top picks for 2024, and more.

Investors remain optimistic about Tandem Diabetes (TNDM), backed by the impressive spree of product introductions.

Tandem Diabetes (TNDM) announces the full U.S. launch of Tandem Source, a new diabetes management platform for customers and healthcare providers.

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system in the world to feature Dexcom's most advanced CGM technology.

Investors remain optimistic about Tandem Diabetes (TNDM), backed by upcoming innovative launches, including Mobi and the new integrated CGM offering.

Tandem Diabetes (TNDM) reports a higher-than-anticipated loss in the third quarter of 2023.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Susan Morrison - EVP & Chief Administrative Officer John Sheridan - Presiden

Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics co

AbbVie has good reasons for investors to take a close look at the stock, even though its best-selling drug recently lost patent exclusivity. Tandem Diabetes Care has plenty of room to increase sales,

Tandem Diabetes Care, Inc. (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in